Protein misfolding in disease and small molecule therapies

Current Topics in Medicinal Chemistry

Volumn 12, Issue 22, 2012, Pages 2460-2469

  Gomes, Cláudio M ^a  

^a INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

Author keywords

Alzheimer's disease; Amyloid; Amyotrophic lateral sclerosis; Folding correctors; Lysosomal diseases; Metabolic diseases; Neurodegenerative diseases; Pharmacological chaperone; Pro teostasis; Protein aggregation; Protein folding; Protein stability

Indexed keywords

1 DEOXYNOJIRIMYCIN; AMYLOID BETA PROTEIN; CHAPERONE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOXYCYCLINE; IVACAFTOR; LUMACAFTOR; MIGLUSTAT; PREALBUMIN; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; TETRAHYDROBIOPTERIN; THYROXINE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CYSTIC FIBROSIS; DISEASES; ENERGY TRANSFER; FAMILIAL AMYLOID POLYNEUROPATHY; GENE MUTATION; HUMAN; LYSOSOME STORAGE DISEASE; MEDICAL PROCEDURES; METABOLIC DISORDER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN MISFOLDING; REVIEW; SMALL MOLECULE THERAPY;

AMYLOID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; LYSOSOMAL STORAGE DISEASES; MOLECULAR TARGETED THERAPY; PREALBUMIN; PROTEIN FOLDING; PROTEIN TRANSPORT; PROTEOSTASIS DEFICIENCIES;

EID: 84874905513     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212220002     Document Type: Review

References (65)

1. Dunker, A. K.; Silman, I.; Uversky, V. N.; Sussman, J. L., Function and structure of inherently disordered proteins. Current opinion in structural biology 2008, 18 (6), 756-764.
2. Braakman, I.; Bulleid, N. J., Protein folding and modification in the mammalian endoplasmic reticulum. Annual review of biochemistry 2011, 80, 71-99.
3. Bukau, B.; Weissman, J.; Horwich, A., Molecular chaperones and protein quality control. Cell 2006, 125 (3), 443-451.
4. Hartl, F. U.; Hayer-Hartl, M., Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 2002, 295 (5561), 1852-1858.
5. Hartl, F. U.; Hayer-Hartl, M., Converging concepts of protein folding in vitro and in vivo. Nature structural & molecular biology 2009, 16 (6), 574-581.
6. Hartl, F. U.; Bracher, A.; Hayer-Hartl, M., Molecular chaperones in protein folding and proteostasis. Nature 2011, 475 (7356), 324-332.
7. Dobson, C. M., Protein folding and misfolding. Nature 2003, 426 (6968), 884-890.
8. Dobson, C. M., The generic nature of protein folding and misfolding. In Protein Misfolding, Aggregation, and conforma tional diseases - Part A: Protein aggregation and conformational diseases, Uversky, V. N.; GFink, A. L., Eds. Springer: New York, 2006; Vol. 4, pp 21-41.
9. Jackson, S. E.; Fersht, A. R., Folding of chymotrypsin inhibitor 2. 1. Evidence for a two-state transition. Biochemistry 1991, 30 (43), 10428-10435.
10. Jackson, S. E., How do small single-domain proteins fold? Folding & design 1998, 3 (4), R81-91.
11. Onuchic, J. N.; Wolynes, P. G., Theory of protein folding. Current opinion in structural biology 2004, 14 (1), 70-75.
12. Thirumalai, D.; O'Brien, E. P.; Morrison, G.; Hyeon, C., Theoretical perspectives on protein folding. Annual review of biophysics 2010, 39, 159-183.
13. Dill, K. A.; Chan, H. S., From Levinthal to pathways to funnels. Nature structural biology 1997, 4 (1), 10-19.
14. Han, J. H.; Batey, S.; Nickson, A. A.; Teichmann, S. A.; Clarke, J., The folding and evolution of multidomain proteins. Nature reviews. Molecular cell biology 2007, 8 (4), 319-330.
15. Brunori, M.; Gianni, S.; Giri, R.; Morrone, A.; Travaglini-Allocatelli, C., Morphogenesis of a protein: folding pathways and the energy landscape. Biochemical Society transactions 2012, 40 (2), 429-432.
16. Ivarsson, Y.; Travaglini-Allocatelli, C.; Brunori, M.; Gianni, S., Mechanisms of protein folding. European biophysics journal: EBJ 2008, 37 (6), 721-728.
17. Pace, C. N.; Shirley, B. A.; McNutt, M.; Gajiwala, K., Forces contributing to the conformational stability of proteins. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 1996, 10 (1), 75-83.
18. Chiti, F.; Dobson, C. M., Protein misfolding, functional amyloid, and human disease. Annual review of biochemistry 2006, 75, 333-366.
19. Gregersen, N.; Bross, P.; Vang, S.; Christensen, J. H., Protein misfolding and human disease. Annual review of genomics and human genetics 2006, 7, 103-124.
20. Chiti, F.; Dobson, C. M., Amyloid formation by globular proteins under native conditions. Nature chemical biology 2009, 5 (1), 15-22.
21. Morello, J. P.; Petaja-Repo, U. E.; Bichet, D. G.; Bouvier, M., Pharmacological chaperones: a new twist on receptor folding. Trends in pharmacological sciences 2000, 21 (12), 466-469.
22. Morello, J. P.; Salahpour, A.; Laperriere, A.; Bernier, V.; Arthus, M. F.; Lonergan, M.; Petaja-Repo, U.; Angers, S.; Morin, D.; Bichet, D. G.; Bouvier, M., Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. The Journal of clinical investigation 2000, 105 (7), 887-895.
23. Serradeil-Le Gal, C.; Lacour, C.; Valette, G.; Garcia, G.; Foulon, L.; Galindo, G.; Bankir, L.; Pouzet, B.; Guillon, G.; Barberis, C.; Chicot, D.; Jard, S.; Vilain, P.; Garcia, C.; Marty, E.; Raufaste, D.; Brossard, G.; Nisato, D.; Maffrand, J. P.; Le Fur, G., Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. The Journal of clinical investigation 1996, 98 (12), 2729-2738.
24. Leandro, P.; Gomes, C. M., Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. Mini Rev Med Chem 2008, 8 (9), 901-911.
25. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W., Adapting proteostasis for disease intervention. Science 2008, 319 (5865), 916-919.
26. Powers, E. T.; Morimoto, R. I.; Dillin, A.; Kelly, J. W.; Balch, W. E., Biological and chemical approaches to diseases of proteostasis deficiency. Annual review of biochemistry 2009, 78, 959-991.
27. Calamini, B.; Morimoto, R. I., Protein homeostasis as a therapeutic target for diseases of protein conformation. Current Topics Medicinal Chemistry 2012, (this issue).
28. Saraiva, M. J.; Magalhaes, J.; Ferreira, N.; Almeida, M. R., Transthyretin deposition in familial amyloidotic polyneuropathy. Current medicinal chemistry 2012, 19 (15), 2304-2311.
29. Johnson, S. M.; Connelly, S.; Fearns, C.; Powers, E. T.; Kelly, J. W., The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. Journal of molecular biology 2012, 421 (2-3), 185-203.
30. Almeida, M. R.; Saraiva, M. J., Clearance of extracellular misfolded proteins in systemic amyloidosis: experience with transthyretin. FEBS letters 2012, 586 (18), 2891-2896.
31. Bulawa, C. E.; Connelly, S.; Devit, M.; Wang, L.; Weigel, C.; Fleming, J. A.; Packman, J.; Powers, E. T.; Wiseman, R. L.; Foss, T. R.; Wilson, I. A.; Kelly, J. W.; Labaudiniere, R., Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America 2012, 109 (24), 9629-9634.
32. Coelho, T.; Maia, L. F.; Martins da Silva, A.; Waddington Cruz, M.; Plante-Bordeneuve, V.; Lozeron, P.; Suhr, O. B.; Campistol, J. M.; Conceicao, I. M.; Schmidt, H. H.; Trigo, P.; Kelly, J. W.; Labaudiniere, R.; Chan, J.; Packman, J.; Wilson, A.; Grogan, D. R., Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012, 79 (8), 785-792.
33. Ferreira, N.; Saraiva, M. J.; Almeida, M. R., Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS letters 2011, 585 (15), 2424-2430.
34. Ferreira, N.; Saraiva, M. J.; Almeida, M. R., Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 2012, 19 Suppl 1, 39-42.
35. Ferreira, N.; Saraiva, M. J.; Almeida, M. R., Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: in vivo evidence from FAP mice models. PloS one 2012, 7 (1), e29933.
36. Obici, L.; Cortese, A.; Lozza, A.; Lucchetti, J.; Gobbi, M.; Palladini, G.; Perlini, S.; Saraiva, M. J.; Merlini, G., Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 2012, 19 Suppl 1, 34-36.
37. Dorfman, R. Cystic Fibrosis Mutation Database http://www.genet.sickkids.on.ca.
38. Lubamba, B.; Dhooghe, B.; Noel, S.; Leal, T., Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. Clinical biochemistry 2012, 45 (15), 1132-1144.
39. Balch, W. E.; Roth, D. M.; Hutt, D. M., Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 2011, 3 (2).
40. Ramsey, B. W.; Davies, J.; McElvaney, N. G.; Tullis, E.; Bell, S. C.; Drevinek, P.; Griese, M.; McKone, E. F.; Wainwright, C. E.; Konstan, M. W.; Moss, R.; Ratjen, F.; Sermet-Gaudelus, I.; Rowe, S. M.; Dong, Q.; Rodriguez, S.; Yen, K.; Ordonez, C.; Elborn, J. S., A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. The New England journal of medicine 2011, 365 (18), 1663-1672.
41. Davis, P. B.; Yasothan, U.; Kirkpatrick, P., Ivacaftor. Nat Rev Drug Discov 2012, 11 (5), 349-350.
42. Yu, H.; Burton, B.; Huang, C. J.; Worley, J.; Cao, D.; Johnson, J. P., Jr.; Urrutia, A.; Joubran, J.; Seepersaud, S.; Sussky, K.; Hoffman, B. J.; Van Goor, F., Ivacaftor potentiation of multiple CFTR channels with gating mutations. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2012, 11 (3), 237-245.
43. Eckford, P. D.; Li, C.; Ramjeesingh, M.; Bear, C. E., CFTR potentiator vx-770 (ivacaftor) opens the defective channel gate of mutant cftr in a phosphorylation-dependent but atp-independent manner. The Journal of biological chemistry 2012.
44. Clancy, J. P.; Rowe, S. M.; Accurso, F. J.; Aitken, M. L.; Amin, R. S.; Ashlock, M. A.; Ballmann, M.; Boyle, M. P.; Bronsveld, I.; Campbell, P. W.; De Boeck, K.; Donaldson, S. H.; Dorkin, H. L.; Dunitz, J. M.; Durie, P. R.; Jain, M.; Leonard, A.; McCoy, K. S.; Moss, R. B.; Pilewski, J. M.; Rosenbluth, D. B.; Rubenstein, R. C.; Schechter, M. S.; Botfield, M.; Ordonez, C. L.; Spencer-Green, G. T.; Vernillet, L.; Wisseh, S.; Yen, K.; Konstan, M. W., Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012, 67 (1), 12-18.
45. Van Goor, F.; Hadida, S.; Grootenhuis, P. D.; Burton, B.; Stack, J. H.; Straley, K. S.; Decker, C. J.; Miller, M.; McCartney, J.; Olson, E. R.; Wine, J. J.; Frizzell, R. A.; Ashlock, M.; Negulescu, P. A., Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences of the United States of America 2011, 108 (46), 18843-18848.
46. Parenti, G., Treating lysosomal storage diseases with pharma cological chaperones: from concept to clinics. EMBO molecular medicine 2009, 1 (5), 268-279.
47. Fan, J. Q.; Ishii, S.; Asano, N.; Suzuki, Y., Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature medicine 1999, 5 (1), 112-115.
48. Schueler, U. H.; Kolter, T.; Kaneski, C. R.; Zirzow, G. C.; Sandhoff, K.; Brady, R. O., Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. Journal of inherited metabolic disease 2004, 27 (5), 649-658.
49. Lieberman, R. L.; Wustman, B. A.; Huertas, P.; Powe, A. C., Jr.; Pine, C. W.; Khanna, R.; Schlossmacher, M. G.; Ringe, D.; Petsko, G. A., Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature chemical biology 2007, 3 (2), 101-107.
50. Wu, X.; Katz, E.; Della Valle, M. C.; Mascioli, K.; Flanagan, J. J.; Castelli, J. P.; Schiffmann, R.; Boudes, P.; Lockhart, D. J.; Valenzano, K. J.; Benjamin, E. R., A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Human mutation 2011, 32 (8), 965-977.
51. Benjamin, E. R.; Khanna, R.; Schilling, A.; Flanagan, J. J.; Pellegrino, L. J.; Brignol, N.; Lun, Y.; Guillen, D.; Ranes, B. E.; Frascella, M.; Soska, R.; Feng, J.; Dungan, L.; Young, B.; Lockhart, D. J.; Valenzano, K. J., Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Molecular therapy: the journal of the American Society of Gene Therapy 2012, 20 (4), 717-726.
52. Khanna, R.; Flanagan, J. J.; Feng, J.; Soska, R.; Frascella, M.; Pellegrino, L. J.; Lun, Y.; Guillen, D.; Lockhart, D. J.; Valenzano, K. J., The pharmacological chaperone AT2220 increases recom binant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PloS one 2012, 7 (7), e40776.
53. Rodrigues, J. V.; Henriques, B. J.; Lucas, T. G.; Gomes, C. M., Cofactors and metabolites as protein folding helpers in metabolic diseases. Current Topics Medicinal Chemistry 2012, (this issue).
54. Thony, B.; Ding, Z.; Martinez, A., Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: implications for tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS letters 2004, 577 (3), 507-511.
55. Staudigl, M.; Gersting, S. W.; Danecka, M. K.; Messing, D. D.; Woidy, M.; Pinkas, D.; Kemter, K. F.; Blau, N.; Muntau, A. C., The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Human molecular genetics 2011, 20 (13), 2628-2641.
56. Pey, A. L.; Ying, M.; Cremades, N.; Velazquez-Campoy, A.; Scherer, T.; Thony, B.; Sancho, J.; Martinez, A., Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. The Journal of clinical investigation 2008, 118 (8), 2858-2867.
57. Santos-Sierra, S.; Kirchmair, J.; Perna, A. M.; Reiss, D.; Kemter, K.; Roschinger, W.; Glossmann, H.; Gersting, S. W.; Muntau, A. C.; Wolber, G.; Lagler, F. B., Novel pharmacological chaperones that correct phenylketonuria in mice. Human molecular genetics 2012, 21 (8), 1877-1887.
58. Underhaug, J.; Aubi, O.; Martinez, A., Phenylalanine hydroxylase misfolding and pharmacological chaperones. Current Topics Medicinal Chemistry 2012, (this issue).
59. Henriques, B. J.; Rodrigues, J. V.; Gomes, C. M., Riboflavin and beta-oxidation Flavoenzymes. In B Vitamins and Folate: Chemistry, Analysis, Function and Effects, The Royal Society of Chemistry: 2012; pp 611-632.
60. Henriques, B. J.; Olsen, R. K.; Bross, P.; Gomes, C. M., Emerging roles for riboflavin in functional rescue of mitochondrial beta-oxidation flavoenzymes. Current medicinal chemistry 2010, 17 (32), 3842-3854.
61. Henriques, B. J.; Rodrigues, J. V.; Gomes, C. M., Riboflavin and beta-oxidation flavoenzymes In B Vitamins: Chemistry, Analysis, Function and Effects, Royal Society of Chemistry/Springer: London, 2012.
62. Cornelius, N.; Frerman, F. E.; Corydon, T. J.; Palmfeldt, J.; Bross, P.; Gregersen, N.; Olsen, R. K., Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Human molecular genetics 2012, 21 (15), 3435-3448.
63. Olsen, R. K.; Olpin, S. E.; Andresen, B. S.; Miedzybrodzka, Z. H.; Pourfarzam, M.; Merinero, B.; Frerman, F. E.; Beresford, M. W.; Dean, J. C.; Cornelius, N.; Andersen, O.; Oldfors, A.; Holme, E.; Gregersen, N.; Turnbull, D. M.; Morris, A. A., ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain: a journal of neurology 2007, 130 (Pt 8), 2045-2054.
64. Henriques, B. J.; Rodrigues, J. V.; Olsen, R. K.; Bross, P.; Gomes, C. M., Role of flavinylation in a mild variant of multiple acyl-CoA dehydrogenation deficiency: a molecular rationale for the effects of riboflavin supplementation. The Journal of biological chemistry 2009, 284 (7), 4222-42229.
65. Mu, T. W.; Ong, D. S.; Wang, Y. J.; Balch, W. E.; Yates, J. R., 3rd; Segatori, L.; Kelly, J. W., Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008, 134 (5), 769-781.